SLITRK4 and colorectal carcinoma: Moreover, the efficacy of immune checkpoint inhibitors is also undesirable because only 5% of CRC patients with metastases have high microsatellite instability (MSI‐H)/mismatch repair defect (dMMR).[41] Recent advances in siRNA nanomedicines with good potency and safety have demonstrated the potential of developing an NP platform for the delivery of siRNA targeting SLITRK4.